Research programme: Japanese encephalitis vaccine - OctoPlus/Takeda
Alternative Names: JEV vaccine - OctoPlus/TakedaLatest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator OctoPlus; SingVax
- Developer OctoPlus; Takeda Pharmaceuticals USA
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Japanese encephalitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Japanese encephalitis(Prevention) in Singapore (Parenteral, Injection)
- 31 May 2013 Inviragen has been acquired by Takeda Pharmaceuticals USA
- 27 Feb 2013 OctoPlus has been acquired by Dr Reddys Laboratories